Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis.
Santisteban M, Solans BP, Hato L, Urrizola A, Mejías LD, Salgado E, Sánchez-Bayona R, Toledo E, Rodríguez-Spiteri N, Olartecoechea B, Idoate MA, López-Díaz de Cerio A, Inogés S. Santisteban M, et al. Among authors: lopez diaz de cerio a. Ther Adv Med Oncol. 2021 Dec 23;13:17588359211064653. doi: 10.1177/17588359211064653. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34987618 Free PMC article.
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Bendandi M, et al. Leuk Lymphoma. 2006 Jan;47(1):29-37. doi: 10.1080/10428190500272473. Leuk Lymphoma. 2006. PMID: 16321824 Clinical Trial.
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group. Inogès S, et al. J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301. doi: 10.1093/jnci/djj358. J Natl Cancer Inst. 2006. PMID: 16985248 Clinical Trial.
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.
Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P. Martinez-Forero I, et al. Eur J Immunol. 2008 Feb;38(2):576-86. doi: 10.1002/eji.200737271. Eur J Immunol. 2008. PMID: 18200504 Free article.
Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M. Inoges S, et al. Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122. Leuk Lymphoma. 2009. PMID: 19152172 Free article.
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, Panizo A, Giraldo P, Rodríguez-Calvillo M, Grande C, Pena E, Olave M, Panizo C, Inogés S. García-Muñoz R, et al. Immunol Res. 2016 Apr;64(2):548-57. doi: 10.1007/s12026-015-8747-9. Immunol Res. 2016. PMID: 26659089
43 results